Waning immunity and booster responses in nursing and medical technology students who had received plasma-derived or recombinant hepatitis B vaccine during infancy

Lin, Ching‐Chiang; Yang, Chun‐Yuh; Shih, Ching‐Tang; Chen, Bai-Hsiun; Huang, Yeou‐Lih

doi:10.1016/j.ajic.2010.07.010

Cited by 17 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,8,11,19,28,[31][32][33][34][35][36][37] Finally, both parameters may also be influenced by the prevalence of hepatitis B infection in the population and the HBsag carrier status of the mothers in the country. 6,7,11,21,22,[28][29][30][31][32][33]35,37,38 all these studies, however, are difficult to compare because results are influenced by a mixture of causes as well as by different follow-up periods.…”

mentioning

confidence: 99%

“…17 We, therefore, focused our study on the duration of protection after infant immunization. although quite a number of studies exist dealing with the persistence of anti-HBs after primary immunization or analyzing the response to a booster dose after anti-HBs has dropped below 10 miu/ml [18][19][20][21][22][23][24][25][26] , there is no systematic investigation assessing determinants for waning immunity.Persistence of anti-HBs ≥ 10 miu/ml and response to booster vaccination 19,21,23 may be related to vaccine dosage, [27][28][29][30] beginning of the primary vaccine regime (at birth or later in infancy), 22,28,29,[31][32][33] timing of the last vaccination of the primary series (ie, the gap time between last and preceding dose), 4,33 numbers of vaccine doses given as primary vaccine series 4 and use of plasma-derived or recombinant vaccines. 4,8,11,19,28,[31][32][33][34][35][36][37] Finally, both parameters may also be influenced by the prevalence of hepatitis B infection in the population and the HBsag carrier status of the mothers in the country.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

“…[44][45][46] differences in the protective effect of plasma versus recombinant vaccines have been under debate for a while. 4,8,11,19,28,34,35,37,47 Comparison of plasma and recombinant vaccines needs to take account of age at follow-up time, vaccination schedules and dosage. in our analysis, we did account for these confounding factors and could not identify differences between plasma and recombinant vaccines.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Determinants of Long-term Protection After Hepatitis B Vaccination in Infancy

Schönberger

Riedel²,

Rückinger³

et al. 2013

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: the duration of protection after hepatitis B vaccination in early infancy is unclear and may be related to vaccination schedule, dosage, vaccine type and population characteristics. Factors potentially influencing waning immunity were assessed. Methods: a systematic review was performed. the main outcomes were prevalence of anti-hepatits B antibodies ≥ 10 miu/ml after primary or booster vaccination. Factors potentially influencing protection were assessed in an adjusted random-effects meta-analysis model by age for both outcomes. results of both meta-analyses were combined in a prognostic model. Results: Forty-six studies reporting on the anti-hepatits B antibodies ≥ 10 miu/ml 5 to 20 years after primary immunization and 29 on booster response were identified. the adjusted meta-analyses identified maternal carrier status (odds ratio [Or]: 2.37 [1.11; 5.08]), lower vaccine dosage than presently recommended (Or: 0.14 [0.06; 0.30]) and gap time between last and preceding dose of the primary vaccine series (Or: 0.44 [0.22; 0.86]) as determinants for persistence of anti-hepatits B antibodies ≥ 10. a lower vaccine dosage was also associated with failure to respond to booster (Or: 0.20 [0.10; 0.38]). the prognostic model predicted long-term protection of 90% [77%; 100%] at the age of 17 years for offspring of noncarrier mothers vaccinated with a presently recommended dose and vaccination schedule. Conclusions: Based on meta-analyses, predictors of waning immunity after hepatitis B vaccination in infancy could be identified. a prognostic model for long-term protection after hepatitis B vaccination in infancy was developed.Key Words: hepatitis B, infant vaccination, booster, long-term protection, determinants of protection (Pediatr Infect Dis J 2013;32: 307-313) A lthough hepatitis B vaccination is highly effective, vaccination failures leading to acute [1][2][3][4][5] and sometimes chronic infection [5][6][7][8] have been observed. although infections occurring within a short time interval after vaccination are likely to reflect primary vaccination failure 1,4 due to nonresponse, those occurring after decades are likely to reflect secondary vaccination failure due to waning immunity. anti-hepatits B antibodies [anti-HBs] ≥ 10 miu/ ml either after primary vaccination or as response to booster if the antibody concentrations have fallen below are widely accepted marker of protection after hepatitis B vaccination. 9-11 immunity against hepatitis B gives protection against infection and protection against disease. 12-14 Protection against infection is based on the presence of anti-HBs ≥ 10 miu/ml. after vaccination against hepatitis B, the proportion of individuals with anti-HBs ≥10 miu/ ml is highly dependent on the time elapsed since primary vaccination. individuals whose anti-HBs concentrations dropped below a level of 10 miu/ml are not protected any more against infection with hepatitis B virus. However, they are not at risk of hepatic disease as long as they have hepatitis B surface antigen (HBsag)-spe...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Determinants of Long-term Protection After Hepatitis B Vaccination in Infancy

Schönberger

Riedel²,

Rückinger³

et al. 2013

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…Hepatitis B surface antibody (HBsAb) levels correlate with the immunity to HBV and levels of anti-HBs antibody are related to the number of doses of vaccine administered (Kubba et al, 2003;Lin et al, 2011).…”

Section: Article Infomentioning

confidence: 99%

Study of Hepatitis B Surface Antibody Titres in Female Medical Students Post Vaccination

Nagamani¹,

Naidu²,

Jayanthi³

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13-18 years after primary vaccination

et al. 2014

View full text Add to dashboard Cite

The question of whether booster doses are required to maintain long-term protection against hepatitis B virus (HBV) after primary vaccination remains to be determined. Thus, the aim of this study was to evaluate the immune memory responses to hepatitis B surface antigen (HBsAg) challenge in vaccinated individuals through an in vitro-specific stimulation assay. Peripheral blood mononuclear cells (4 × 10(6) cells/ml) were stimulated with 50 ng/ml of recombinant HBsAg. In vitro anamnestic antibody responses, as shown by detection of high avidity antibody in culture supernatants, were found 13-18 years after primary vaccination and were not correlated with serum antibodies (r = -0.177; P = 0.377). In addition, the findings from this study indicate that immune memory against hepatitis B was well preserved in 40.0% and 60.0% of vaccinees with anti-HBs levels less than 10 IU/L or lacking serum antibodies altogether, respectively. In conclusion, the data suggest the presence of immunological memory in vaccinated individuals, including those who showed anti-HBs <10 IU/L or undetectable antibody.

show abstract

Waning immunity and booster responses in nursing and medical technology students who had received plasma-derived or recombinant hepatitis B vaccine during infancy

Cited by 17 publications

References 34 publications

Determinants of Long-term Protection After Hepatitis B Vaccination in Infancy

Determinants of Long-term Protection After Hepatitis B Vaccination in Infancy

Study of Hepatitis B Surface Antibody Titres in Female Medical Students Post Vaccination

Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13-18 years after primary vaccination

Contact Info

Product

Resources

About